Author

A. Beuve

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Assay:clinical cohort / trial· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:metabolomics· 1 Assay:proteomics· 1

Frequent Co-Authors

A. C. Lockhart· 1 shared B. Mateo-Victoriano· 1 shared C. I. Troccoli· 1 shared D. Kwon· 1 shared E. N. Jackson· 1 shared J. L. Gulley· 1 shared J. Sharma· 1 shared L. Misiara· 1 shared

Activity by Year

2023-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. C. Lockhart

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

The soluble guanylyl cyclase pathway is inhibited to evade androgen deprivation-induced senescence and enable progression to castration resistance

P. Rai, L. Zhang, C. I. Troccoli, B. Mateo-Victoriano, L. Misiara, E. N. Jackson, P. Shu, T. M. Plastini, W. Tao, D. Kwon, X. Chen, J. Sharma, M. Jorda, J. L. Gulley, M. Bilusic, , A. Beuve

This study identifies the soluble guanylyl cyclase (sGC) pathway as a target for castration-resistant prostate cancer (CRPC) treatment, showing that riociguat inhibits CRPC growth and enhances radiation response.

bioRxiv · May 3, 2023 · PreprintCancer Biology